Japan· JP-4291086M1025
レポトレクチニブ
A repotrectinib product containing レポトレクチニブ, registered in Japan by ブリストル・マイヤーズ スクイブ, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Repotrectinib is registered in 10 of 19 countries.
Countries holding a registration under ATC L01EX28 (repotrectinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 6 of them publish a price we can compare per daily dose
Repotrectinib · ATC L01EX28
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- レポトレクチニブ
- Manufacturer
- ブリストル・マイヤーズ スクイブ
- Country
- Japan (JP)
- ATC code
- L01EX28
- ATC class
- Repotrectinib
- Defined daily dose
- 0.32 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L01EX28
Repotrectinib, as other registers publish it.
- IcelandAugtyroBristol-Myers Squibb Pharma EEIG
- NorwayAugtyroBristol-Myers Squibb Pharma EEIG
- United StatesAugtyroE.R. Squibb & Sons, L.L.C.
- United StatesAugtyroE.R. Squibb & Sons, L.L.C.
- IcelandAugtyroBristol-Myers Squibb Pharma EEIG
- United StatesAugtyroE.R. Squibb & Sons, L.L.C.
- United StatesAugtyroE.R. Squibb & Sons, L.L.C.
- NorwayAugtyroBristol-Myers Squibb Pharma EEIG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d5e825bb-bd35-488d-8cb6-6e055ab624f6 GET /v1/drugs/d5e825bb-bd35-488d-8cb6-6e055ab624f6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４０ｍｇ１カプセル",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291086M1025",
"category": "内用薬",
"price_yen": 3468.3,
"generic_name": "レポトレクチニブ",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about repotrectinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.